THERAPY DOSSIER · th-89189ca5aa4c

Malva sylvestris extract loaded into polyurethane/carboxymethylcellulose nanofibre wound dressing

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05138484 ↗PHASE3completed

Clinical Evaluation of a Mouthwash Containing Malva Sylvestris Extract in Reducing Oral Biofilm and Gingival Inflammation

Periodontal Diseases

Enrolment: 54 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32994005 ↗2020Reported benefit

Polyurethane/carboxymethylcellulose nanofibers containing Malva sylvestris extract for healing diabetic wounds: Preparation, characterization, in vitro and in vivo studies.

RatWoundTopical, applied as a nanofibre wound dressingExtract loadings of 5, 10, 15 and 20% w/w in the nanofibre…

Model: Excisional skin wound in diabetic rats

Mean healing rate at day 14 was 32.1 plus or minus 0.2% for gauze, 51.4 plus or minus 0.4% for polyurethane/carboxymethylcellulose and 71 plus or minus 0.14%, 87.64 plus or minus 1.02%, 95.05 plus or minus 0.24% and 95.11 plus or minus 0.2% for the 5, 10, 15 and 20% w/w extract dressings respective…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…